



3Q 2024 Financial Results Presentation

November 2024

Disclaimer

This presentation was prepared by NewMed Energy Limited Partnership (the “Partnership”) and is given to you only for the provision of concise information for the sake of convenience and may not be copied or distributed to any other person. The Data and information included in this presentation should not be interpreted as advice and should not be relied on for any purpose. Such data and information should not be copied or used except as expressly permitted in writing.

This presentation does not purport to be comprehensive or to contain any and all information which might be relevant in connection with the making of a decision on an investment in securities of the Partnership.

No explicit or implicit representation or undertaking is given by any person regarding the accuracy or integrity of any information included in this presentation. In particular, no representation or undertaking is given regarding the realization or reasonableness of any forecasts regarding the future chances of the Partnership.

To obtain a full picture of the activities of the Partnership and the risks entailed thereby, see the full immediate and periodic reports filed by the Partnership with the Israel Securities Authority and the Tel Aviv Stock Exchange Ltd., including warnings regarding forward-looking information, as defined in the Securities Law, 5728-1968, included therein. The forward-looking information in the presentation may not materialize, in whole or in part, or may materialize differently than expected, or may be affected by factors that cannot be assessed in advance.

For the avoidance of doubt, it is clarified that the Partnership do not undertake to update and/or modify the information included in the presentation to reflect events and/or circumstances occurring after the date of preparation of the presentation.

This presentation is not an offer or invitation to buy or subscribe for any securities. This presentation and anything contained herein are not a basis for any contract or undertaking and are not to be relied upon in such context. The information provided in the presentation is not a basis for the making of any investment decision, nor a recommendation or an opinion, nor a substitute for the discretion of a potential investor.

Key Highlights

- ❑ 3rd. quarter gas production – c. 1,189 MMcf/d (209 Mboe/d), 3.10 BCM
- ❑ 3rd. quarter earnings – \$221mm EBITDA / \$147mm net profit
- ❑ Leviathan Operational Update :
 - 3rd GL project
 - Leviathan Phase 1B FEED underway
- ❑ Financing : Deleveraging and preparing for a new investment cycle
- ❑ Dividend – \$65mm Dividend distribution for the quarter.



Production Summary


	Israel	Egypt	Jordan	Total
3Q / 2024 (BCM)	0.5	1.8	0.8	3.1
Average Price (\$/mmbtu)				6.18
3Q / 2023 (BCM)	0.4	1.7	0.8	2.9
Average Price (\$/mmbtu)				6.06

* Production Summary for Leviathan 100%





Price Environment








Leviathan Operations

6


- ❑ Non-material gas supply disruptions due the ongoing conflict
- ❑ 3rd Gathering Line project. First Gas expected End 2025 (originally Mid 2025)
- ❑ Phase 1B FEED – Progressing on FEED and long lead procurement agreements





Regional Connectivity Update


- 1 INGL Ashdod-Ashkelon, EMG pipeline Debottleneck using Full capacity of EMG – 800mmc/d – 4Q 2025
- 2 FAJR + compression – Additional 400 mmcf/d – 2H 2026
- 3 Nitzana pipeline project – 600 mmcf/d – 1H 2028






Key 3rd Quarter Financial Metrics (\$mm)


Sales



EBITDA



Net Profit






P&L Summary (\$mm)

For the period	7-9/2024	7-9/2023	2023
Revenues From natural gas and condensate sales	313.6	285.8	1,094.4
Net of royalties	46.0	41.9	159.8
Revenues, net	267.6	243.9	934.6
Expenses and costs:			
Cost of production of natural gas and condensate	40.5	37.0	148.6
Depreciation, depletion and amortization expenses	25.6	19.3	79.2
Other direct expenses	1.4	1.1	5.3
G&A	5.1	5.0	20.8
Total expenses and costs	72.6	62.4	253.9
The Partnership's share in the losses / Profits of a company accounted for at equity	-	(0.7)	(1.3)
Operating profit	195.0	180.8	679.4
Financial expenses	(27.4)	(30.5)	(133.8)
Financial income	24.2	7.8	28.7
Financial expenses, net	(3.2)	(22.7)	(105.1)
Profit before income taxes	191.8	158.1	574.3
Taxes on income	(44.5)	147.3	(142.8)
Profit from continued operation	147.3	117.9	431.5
Total profit from discontinued operations	(0.3)	-	2.1
Net income	147.0	117.9	433.6




3rd Quarter Change in Net Profit (\$mm)



Financial Debt (\$'B)

- ❑ NewMed's Leviathan Bond buy back amounts to \$91mm. Board approved additional buyback plan of \$100mm Leviathan Bonds.
- ❑ Agreements for the provision of credit facilities totaling \$400mm
- ❑ \$433.1mm cash and deposits for the quarter
- ❑ Deleveraging ahead of a new investment cycle



* Leviathan Bond Debt



Balance Sheet

Summary (\$mm)

For the Period Ending	30.09.2024	30.09.2023	31.12.2023
Assets:			
Current assets:			
Cash and cash equivalents	157.4	17.3	29.1
Short-term deposits	275.7	38.7	157.6
Trade receivables	240.8	227.9	194.5
Trade and other receivables	108.9	140.9	187.1
Current taxes receivable	-	4.0	
	782.8	428.8	568.3
Non-current assets:			
Investments in oil and gas assets	2,689.5	2,604.0	2,647.3
Investments in a company accounted for at equity	60.7	57.6	58.4
Long-term deposits	0.5	100.7	101.9
Other long-term assets	516.2	536.6	470.3
	3,266.9	3,298.9	3,277.9
	<u>4,049.7</u>	<u>3,727.7</u>	<u>3,846.2</u>
Liabilities and equity:			
Current liabilities:			
Current maturities of bonds	552.9	-	-
Short term banks Loan	-	15.0	80.0
Income tax payable	35.0	-	27.7
Trade and other payables	155.8	115.9	101.1
Other short-term liabilities	2.9	2.5	2.2
	746.6	133.4	211.0
Non-current liabilities:			
Bonds	1,139.3	1,734.1	1,735.1
Deferred taxes	353.3	330.5	313.9
Other long-term liabilities	77.6	69.3	73.7
	1,570.2	2,133.9	2,122.7
Equity:			
Partners' equity	154.8	154.8	154.8
Capital reserves	(28.1)	(28.8)	(28.6)
Retained earnings	1,606.2	1,334.4	1,386.3
	1,732.9	1,460.4	1,512.5
	<u>4,049.7</u>	<u>3,727.7</u>	<u>3,846.2</u>



Upstream Activities


Aphrodite

- The Aphrodite JV Partners have submitted a Development Plan to MECI, which is currently under review and seeking approval



Morocco – Boujdour License


- Processing and analyzing the available data



Dividends

- \$65mm profit distribution for the quarter
- Approximately \$1bn returned to unitholders in profit distribution from Leviathan start up*

Dividend Distributions



* Including latest declared Dividend and tax balancing distribution



Thank You

NewMed Energy- IR
Tel. +972 9 971 2421
IR@newmedenergy.com



Appendix



Leviathan Bond Sponsor Financial Data Report

QUARTER ENDED		30.09.2024
		QUANTITY/ACTUAL AMOUNT (IN USD\$,000)
Total Offtake (BCM)		3.1
Leviathan Revenues (100%)		691,700
Loss Proceeds, if any, paid to Revenue Account		-
Sponsor Deposits, if any, into Revenue Account		-
Gross Revenues (before Royalties)		331,692
Overriding Royalties		
Statutory Royalties		(35,994)
(b) Third Party Royalties		(14,276)
Net Revenues		281,422
Costs and Expenses:		
Fees Under the Financing Documents (Interest Income)		1,215
Taxes		(21,960)
Operation and Maintenance Expenses		(39,353)
Capital Expenditures		(4,915)
Insurance (income)		(11,210)
Total Costs and Expenses (sum of Items H(a), (b), (c), (d) and (e))		(76,223)
Total Cash Flows Available for Debt Service (Item G minus Item H)		205,199
Total Cash Flow from operation (Item G minus Items H(c) and H(e))		230,859
Total Debt Service		35,173
Total Distribution to the Sponsor		74,500

Total offtake (BCM) and Leviathan Revenue for 100% of the Leviathan partners on an accrual basis.